Cancer doctors are lobbying for changes to House-passed drug pricing legislation after an Avalere Health study found the bill would cut an average 40% off the Medicare add-on payment to doctors for administering drugs that are subject to negotiation. The Community Oncology Alliance wants the Senate to continue Medicare’s current policy of paying doctors a drug’s average sales price in the commercial market plus 6%, as opposed to the House bill’s new policy of paying doctors 106% of a drug’s...